Paper Details

  1. Home
  2. Paper Details

Entinostat, a selective HDAC1/2 inhibitor, potentiates the effects of olaparib in homologous recombination proficient ovarian cancer.

Author: CliveMakena L, CrispensMarta A, CybullaEmily, FuhKatherine C, GodwinAndrew K, GuptaVijayalaxmi G, HirstJeff, JewellAndrea, KhabeleDineo, KuschMeghan, PathakHarsh B, PetersenShariska, RobyKatherine F, VindigniAlessandro, WilsonAndrew J, ZhouHelen

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

PARPi inhibitors are effective against ovarian tumors with BRCA1/2 mutations, but other subtypes, including those with CCNE1 amplification, require alternative treatments. This study provides preclinical evidence supporting a clinical trial investigating the combination of olaparib (a PARPi) and entinostat (a histone deacetylase inhibitor) for recurrent HR-proficient ovarian cancer.
Paper Details　
Original Abstract of the Article :
Poly ADP ribose polymerase inhibitors (PARPi) are most effective in BRCA1/2 mutated ovarian tumors. Better treatments are needed for homologous recombination HR-proficient cancer, including CCNE1 amplified subtypes. We have shown that histone deacetylase inhibitors (HDACi) sensitize HR-proficient ov...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/33867143

データ提供：米国国立医学図書館（NLM）

Unlocking New Treatment Strategies for Ovarian Cancer

[Ovarian cancer] is a formidable foe, and finding effective treatments for patients with [homologous recombination-proficient (HR-proficient) ovarian cancer] remains a significant challenge. This study investigates the potential of combining [entinostat], a selective HDAC1/2 inhibitor, with [olaparib], a PARPi, to combat this aggressive form of cancer. Imagine a valiant knight facing a fearsome dragon, representing the challenges of treating HR-proficient ovarian cancer. The knight's arsenal of weapons includes entinostat and olaparib, promising new strategies for conquering this deadly foe.

A Synergistic Approach: Combining Forces to Fight Cancer

The study reveals that combining entinostat with olaparib shows promising preclinical results in sensitizing HR-proficient ovarian cancer cells to treatment. It's like the knight strategically combining different weapons to maximize their effectiveness against the dragon. The authors believe this combination holds promise as a potential treatment option for patients with this challenging form of cancer.

A Path to Personalized Treatment: Tailoring Therapy to Individual Needs

The study highlights the need for further research to evaluate the efficacy and safety of this combination in clinical trials. It's like conducting a thorough reconnaissance mission before launching a full-scale attack on the dragon. The authors emphasize the importance of personalized medicine, tailoring treatment strategies to the specific needs of each patient.

Dr. Camel's Conclusion

This study offers a glimmer of hope in the fight against ovarian cancer. It's a reminder that even in the face of formidable challenges, scientific ingenuity can pave the way for new treatment strategies. The study encourages continued research and clinical evaluation of this combination therapy to explore its potential for improving patient outcomes.

Date :
  1. Date Completed 2021-12-30
  2. Date Revised 2022-07-16
Further Info :

Pubmed ID

33867143

DOI: Digital Object Identifier

NIHMS1749878

Related Literature

Article Analysis
・Effects of olaparib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.